One of the key barriers limiting procurement and access to essential reproductive health medicines is affordability in low-resource settings.
The price of a mifepristone/misoprostol (combi-pack) is currently marked by significant variances. Concept Foundation has developed a cost of goods sold (COGS) model which identifies the key price components of the combi-pack. The model demonstrates the feasibility of lowering the cost of quality-assured combi-packs through reducing mifepristone API cost and selection of the manufacturing location. However, Concept Foundation concludes that such price reduction requires manufacturers to be incentivized to achieve WHO pre-qualification with a carefully built business case and support in identifying and sourcing competitively priced material and manufacturing products to the necessary international standard.